8-K: Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Aardvark Therapeutics announced its full year 2024 financial results, highlighting clinical progress with ARD-101 in Prader-Willi Syndrome and a successful IPO.

Summary

• Aardvark Therapeutics reported its financial results for the year ended December 31, 2024.
• The company's lead candidate, ARD-101, showed clinical activity and was generally well tolerated in a Phase 2 trial for Prader-Willi Syndrome (PWS).
• The Phase 2 trial showed meaningful reductions in hyperphagia, with an average reduction of approximately 8 points among subjects that followed the trial protocol.
• DEXA scans from the PWS Phase 2 trial indicated a trend toward decreased body fat (approximately 1.5%) and increased lean muscle (over 2%) following 28 days of ARD-101 dosing.
• The ongoing ARD-101 Phase 3 HERO trial for hyperphagia associated with PWS is expected to generate topline data in early 2026.
• Aardvark completed its Initial Public Offering (IPO) in February 2025, bolstering its cash runway with $97.9 million in gross proceeds.
• The company's cash, cash equivalents, and short-term investments were $73.7 million as of December 31, 2024, not including the IPO proceeds.
• Aardvark believes its existing cash, cash equivalents, and short-term investments, along with IPO proceeds, will fund projected operations into 2027.
• Research and development expenses were $17.4 million for the year ended December 31, 2024, compared to $4.5 million in 2023.
• General and administrative expenses were $5.3 million for the year ended December 31, 2024, compared to $2.2 million in 2023.
• The net loss was $20.6 million for the year ended December 31, 2024, compared to $7.2 million in 2023.
• The company anticipates initiating a Phase 2 trial of ARD-101 for hypothalamic obesity and a Phase 2 trial of ARD-201 for obesity and related conditions in the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful IPO, promising clinical trial results, and plans for future trials. However, increased expenses and net losses temper the overall outlook.

Positives

• ARD-101 showed positive clinical activity in a Phase 2 trial for PWS, including reductions in hyperphagia and improvements in body composition.
• The company successfully completed its IPO, providing substantial funding for ongoing and future pipeline development.
• Existing cash, cash equivalents, and short-term investments, along with IPO proceeds, are expected to fund operations into 2027.
• The company is advancing its clinical pipeline with the initiation of the Phase 3 HERO trial.
• Executive leadership and board expertise have been strengthened with new appointments.

Negatives

• The company experienced a net loss of $20.6 million for the year ended December 31, 2024, which is higher than the $7.2 million loss in 2023.
• Research and development expenses increased significantly to $17.4 million for the year ended December 31, 2024.
• General and administrative expenses also increased to $5.3 million for the year ended December 31, 2024.

Risks

• The company's future results are subject to uncertainties related to potential delays in clinical trials.
• There is a risk that the company may use its capital resources sooner than expected.
• The company is dependent on third parties for manufacturing, shipping, and clinical trials.
• Results from earlier clinical trials may not be predictive of future results.

Future Outlook

Aardvark anticipates initiating Phase 2 trials for ARD-101 in hypothalamic obesity and ARD-201 in obesity-related conditions in the second half of 2025, with topline data from the Phase 3 HERO trial expected in early 2026. The company believes its current cash resources will fund operations into 2027.

Management Comments

• Tien Lee, M.D., Founder and Chief Executive Officer of Aardvark, stated that Aardvark believes there is a significant, untapped opportunity to target anti-hunger signaling to treat metabolic rare diseases and obesity.
• ARD-101 is intended to address hunger by lowering the discomfort of fasting without notably decreasing the appeal of food or inducing nausea, according to Tien Lee, M.D.

Industry Context

Aardvark is focusing on the distinct neural signaling pathway of hunger, separate from appetite, to develop therapeutics for PWS and metabolic diseases. This approach differentiates them from many approved obesity medications, including GLP-1RA agents, which primarily regulate appetite.

Comparison to Industry Standards

• The company is developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions.
• Other companies developing treatments for Prader-Willi Syndrome include Soleno Therapeutics (Diazoxide Choline) and Zafgen (Beloranib, development discontinued).
• Aardvark's focus on hunger as a distinct target differentiates it from companies primarily targeting appetite, such as Novo Nordisk (Wegovy, Semaglutide) and Eli Lilly (Zepbound, Tirzepatide).

Stakeholder Impact

• Shareholders benefit from the successful IPO and potential for future growth.
• Employees benefit from increased personnel-related expenses and a strengthened executive team.
• Patients with PWS and other metabolic diseases may benefit from the development of new treatments.
• The company's suppliers and partners may benefit from increased research and development activities.

Next Steps

• Initiation of the Phase 2 HONOR trial of ARD-101 for the treatment of hyperphagia associated with acquired hypothalamic obesity is expected in the second half of 2025.
• Initiation of the Phase 2 EMPOWER trial of ARD-201 for the treatment of obesity and obesity-related conditions as a fixed-dose combination of ARD-101 with a dipeptidyl peptidase-4 (DPP-4) inhibitor is expected in the second half of 2025.
• Topline data from the Phase 3 HERO trial for the treatment of hyperphagia associated with PWS is expected in early 2026.

Key Dates

Keywords

Aardvark Therapeutics, ARD-101, ARD-201, Prader-Willi Syndrome, Hyperphagia, Obesity, Clinical Trials, IPO, Financial Results, Metabolic Diseases